Instead, Grundfest attributes the decline in class actions to what he calls the "less fraud hypothesis"--namely, that corporate executives are filing more honest financial statements than in the past because the penalties for cooking them have increased.
Despite these positive attributes, we have modest expectations for Invokana and the SGLT-2 class because the drug and class are associated with a relatively high rate of genital infections which will limit uptake in our view.